Octreotide acetate in the treatment of fluorouracil-induced diarrhea

Oncologist

Volumn 3, Issue 1, 1998, Pages 50-53

  Goumas, Panos ^a,b   Naxakis, Stefanos ^a   Christopoulou, Athina ^a   Chrysanthopoulos, Costas ^a   Nikolopoulou, Vasiliki ^a   Kalofonos, Haralambos P ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

5 fluorouracil; Diarrhea; Octreotide acetate

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; OCTREOTIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031882537     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-1-50     Document Type: Article

References (19)

1. Baillie-Johnson HR. Octreotide in the management of treatment-related diarrhea. Anticancer Drugs 1996;7(suppl 1):11-15.
2. Petrelli NJ, Douglas H, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-1426.
3. Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alpha 2a in the treatment of colorectal carcinoma. Semin Oncol 1990;17(suppl 1): 16-21.
4. Cascinu S, Fedeli A, Fedeli SL et al. Control of chemotherapy induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 1994;51:70-73.
5. Reichlin S. Somatostatin (part I). N Engl J Med 1983;309:1495-1501.
6. Reichlin S. Somatostatin (part II). N Engl J Med 1983;309:1556-1563.
7. Sheppard MC, Shapiro B, Pimstone B et al. Metabolic clearance and plasma half disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979;48:50-53.
8. Bauer W, Briner U, Doefner W et al. SMS, 201-295: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-1140.
9. Wood AJJ. Octreotide. N Engl J Med 1996;334:246-254.
10. Petrelli NJ, Rodriguez-Bigas M, Rustum Y et al. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy induced diarrhea in patients with colorectal carcinoma. Cancer 1993;72:1543-1546.
11. Gebbia V, Carreca I, Testa A et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993;4:443-445.
12. National Cancer Institute: Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, Bethesda, MD:National Cancer Institute, 1988.
13. Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analogue octreotide acetate in the treatment of fluoropyramidine-induced diarrhea. J Clin Oncol 1995:13:222-226.
14. Katz MD, Erstad BL. Octreotide: a new somatostatin analogue. Clin Pharmacol 1989;8:255-301.
15. Karalis K, Mastorakos G, Crhroussos GP et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93:2000-2006.
16. Warhurst G, Turuberg LA, Higgs NB et al. Multiple G-protein dependent pathways mediate the anti-secretory effects of somatostatin and clonidine in the HT-29A-19A colonic cell line. J Clin Invest 1993;92:603-611.
17. Ajani JA, Chestnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer 1993;29:2332-2334a.
18. Kennedy P, Presant CA, Blayney D et al. Sandostatin therapy for chemotherapy and radiotherapy related diarrhea. Proc Am Soc Clin Oncol 1990;9:324-327.
19. Cascinu S, Fedeli A, Luzi-Fedeli S et al. Octreotide versus oral loperamide in the treatment of fluorouracil-induced diarrhea. A randomized trial. J Clin Oncol 1993;11:148-151.